Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

Kerstin Maria Kampa-Schittenhelm(University Children's Hospital Tübingen), Marcus M. Schittenhelm(University Children's Hospital Tübingen)

Molecular Cancer

January 1, 2013

10.1186/1476-4598-12-19

Cited by 121

Related Papers

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

|BMC Cancer|2016|33